文献速递角膜与眼表疾病

抗炎方法调节接触镜不适:一项随机对照试验

Modulating Contact Lens Discomfort With Anti-Inflammatory Approaches: A Randomized Controlled Trial.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2018-01-01

该随机对照试验纳入72名接触镜不适(CLD)成人,比较口服鱼油、口服鱼油+亚麻籽油、omega-3滴眼液与安慰剂12周的效果,并在第12周后给安慰剂组加用0.1%氟米龙滴眼液2周。口服鱼油可降低CLDEQ-8评分,各omega-3干预及氟米龙可降低泪液IL-17A和IL-6水平。

要点

  • 口服鱼油12周可减轻接触镜不适症状(CLDEQ-8评分降低)。
  • 口服鱼油和omega-3滴眼液均降低泪液IL-17A,口服鱼油组降幅63.2%。
  • 0.1%氟米龙滴眼液每日三次用2周可降低泪液IL-17A和IL-6。

核心结论

  • 口服长链omega-3补充12周可减轻接触镜不适。
  • 短期局部糖皮质激素和长期omega-3补充均能降低泪液促炎细胞因子IL-17A和IL-6水平。

研究设计与样本

  • 随机对照试验,72名接触镜不适成人按1:1:1:1随机分为四组。
  • 干预12周,第4周和第12周随访;第12周后安慰剂组接受0.1%氟米龙滴眼液每日三次治疗2周。

主要发现

  • 第12周口服鱼油组CLDEQ-8评分较基线降低7.3±0.8单位(n=17,P<0.05),安慰剂组降低3.5±0.9单位(n=16)。
  • 氟米龙治疗2周后泪液IL-17A降低71.1±14.3%(n=12),IL-6降低47.6±17.5%(n=12,P<0.05)。
  • 第12周口服鱼油组泪液IL-17A降低63.2±12.8%(n=12,P<0.05),omega-3滴眼液组降低76.2±10.8%(n=10,P<0.05),安慰剂组降低3.8±12.7%(n=12)。
  • 第12周所有omega-3干预组泪液IL-6相对安慰剂均降低(P<0.05)。

关键数值与推荐

  • 口服鱼油剂量:每日900 mg EPA + 600 mg DHA。
  • 口服鱼油+亚麻籽油剂量:每日900 mg EPA + 600 mg DHA + 900 mg α-亚麻酸。
  • omega-3滴眼液浓度:0.025% EPA + 0.0025% DHA,每日四次。
  • 氟米龙滴眼液:0.1%,每日三次,用2周。

临床怎么用

  • 对于接触镜不适患者,可考虑口服长链omega-3补充12周以改善症状。
  • 短期局部糖皮质激素可用于调节眼部炎症,但需注意其适用人群和疗程。

局限性

  • 研究仅观察12周(氟米龙2周),长期疗效和安全性未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the efficacy of anti-inflammatory approaches, comprising a topical corticosteroid and omega-3 supplements, for modulating the inflammatory overlay associated with contact lens discomfort (CLD). METHODS: This randomized controlled trial involved 72 adults with CLD, randomized (1:1:1:1) to one of the following: placebo (oral olive oil), oral fish oil (900 mg/d eicosapentaenoic acid [EPA] + 600 mg/d docosohexaenoic acid [DHA]), oral combined fish+flaxseed oils (900 mg/d EPA + 600 mg/d DHA + 900 mg/d alpha-linolenic acid), or omega-3 eye-drops (0.025% EPA + 0.0025% DHA four times per day [qid]) for 12 weeks, with visits at baseline, weeks 4 and 12. At week 12, participants who received placebo were assigned a low-potency corticosteroid (fluorometholone [FML] 0.1%, drops, three times per day [tid]) for 2 weeks (week 14). RESULTS: Sixty-five participants completed the primary endpoint. At week 12, contact lens dry-eye questionnaire (CLDEQ-8) score was reduced from baseline with oral fish oil (-7.3 ± 0.8 units, n = 17, P < 0.05), compared with placebo (-3.5 ± 0.9 units, n = 16). FML produced significant reductions in tear IL-17A (-71.1 ± 14.3%, n = 12) and IL-6 (-47.6 ± 17.5%, n = 12, P < 0.05) relative to its baseline (week 12). At week 12, tear IL-17A levels were reduced from baseline in the oral fish oil (-63.2 ± 12.8%, n = 12, P < 0.05) and topical omega-3 (-76.2 ± 10.8%, n = 10, P < 0.05) groups, compared with placebo (-3.8 ± 12.7%, n = 12). Tear IL-6 was reduced with all omega-3 interventions, relative to placebo (P < 0.05) at week 12. CONCLUSIONS: CLD was attenuated by oral long-chain omega-3 supplementation for 12 weeks. Acute (2 week) topical corticosteroids and longer-term (12 week) omega-3 supplementation reduced tear levels of the proinflammatory cytokines IL-17A and IL-6, demonstrating parallels in modulating ocular inflammation with these approaches.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Downie LE, Gad A, Wong CY, et al. Modulating Contact Lens Discomfort With Anti-Inflammatory Approaches: A Randomized Controlled Trial. Invest Ophthalmol Vis Sci. 2018. PMID: 30046817. doi:10.1167/iovs.18-24758

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。